Profile data is unavailable for this security.
About the company
Chemclin Diagnostics Co Ltd is a China-based company mainly engaged in the research and development of clinical immuno chemiluminescence diagnostic test reagents and instruments. The Company's products are LiCA series of diagnostic reagents based on light-induced chemiluminescence and Chemclin series of diagnostic reagents and instruments based on enzymatic chemiluminescence, which are mainly used in infectious diseases (such as hepatitis B, hepatitis C, Acquired Immunodeficiency Syndrome, syphilis, hepatitis A, hepatitis E) detection of markers, tumor markers, thyroid hormones, reproductive endocrine hormones, diabetes, myocardial markers and inflammation. The Company mainly operates its businesses in the domestic market.
- Revenue in CNY (TTM)353.33m
- Net income in CNY56.49m
- Incorporated2007
- Employees629.00
- LocationChemclin Diagnostics Co LtdNo. 7 Fengxian M. Road, Haidian DistrictBEIJING 100094ChinaCHN
- Phone+86 1 058717511
- Fax+86 1 058717501
- Websitehttp://www.chemclin.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maider Medical Industry Equipment Co Ltd | 279.92m | -18.77m | 2.89bn | 657.00 | -- | 3.59 | -- | 10.33 | -0.1053 | -0.1053 | 1.68 | 4.85 | 0.249 | 1.07 | 2.08 | 426,058.40 | -3.34 | 5.79 | -4.30 | 6.86 | 34.68 | 49.32 | -13.40 | 16.23 | 1.91 | -- | 0.0705 | 63.92 | -42.77 | 5.58 | -120.02 | -- | 22.08 | -- |
| Jiangsu Cowin Biotech Co Ltd | 167.17m | -137.72m | 2.91bn | 833.00 | -- | 2.10 | -- | 17.43 | -1.24 | -1.24 | 1.51 | 12.36 | 0.1038 | 1.81 | 2.52 | 200,679.40 | -8.91 | 2.79 | -9.42 | 2.97 | 45.15 | 68.50 | -85.88 | 11.47 | 13.54 | -- | 0.0156 | 32.07 | -26.54 | 11.23 | -86.25 | -- | 34.36 | -- |
| Shanghai General Hthy Info & Tech Co Ltd | 393.61m | 8.92m | 2.96bn | 355.00 | 338.67 | 2.74 | -- | 7.53 | 0.0644 | 0.0644 | 2.89 | 7.94 | 0.2601 | 3.05 | 0.7735 | 1,108,747.00 | 0.6908 | 7.98 | 0.9681 | 10.00 | 29.15 | 50.08 | 2.66 | 26.00 | 1.82 | 4.30 | 0.1357 | 15.97 | 3.51 | 1.18 | -45.80 | -18.76 | 7.19 | -- |
| Jinan High-tech Development Co Ltd | 324.74m | -841.90m | 3.03bn | 565.00 | -- | 69.16 | -- | 9.34 | -1.03 | -1.03 | 0.3748 | 0.0496 | 0.142 | 0.4155 | 0.8567 | 574,762.40 | -39.48 | -8.01 | -161.56 | -27.24 | 16.82 | 28.09 | -277.95 | -31.77 | 0.8954 | -- | 0.283 | -- | -48.02 | -26.91 | -747.31 | -- | -48.67 | -- |
| Allgens Medical Technology Co Ltd | 213.78m | -3.61m | 3.05bn | 271.00 | -- | 2.13 | -- | 14.27 | -0.0374 | -0.0374 | 1.54 | 10.47 | 0.138 | 1.19 | 2.90 | 788,855.10 | -0.3699 | 5.24 | -0.3882 | 5.61 | 64.91 | 81.42 | -2.68 | 30.31 | 16.62 | -- | 0.029 | 6.47 | -9.03 | 4.09 | -123.35 | -- | -29.51 | -- |
| Chemclin Diagnostics Co Ltd | 353.33m | 56.49m | 3.16bn | 629.00 | 55.94 | 2.24 | -- | 8.93 | 0.1407 | 0.1407 | 0.8799 | 3.51 | 0.1957 | 1.06 | 16.07 | 561,724.90 | 3.13 | 9.46 | 3.44 | 10.57 | 66.36 | 73.98 | 15.99 | 30.72 | 6.62 | -- | 0.1472 | 44.55 | -2.03 | -0.8218 | -13.77 | -2.00 | 14.24 | -- |
| Kontour XiAn Medical Technology Co Ltd | 332.92m | 88.40m | 3.21bn | 311.00 | 36.28 | 4.66 | -- | 9.63 | 1.09 | 1.09 | 4.10 | 8.47 | 0.4356 | 2.73 | 38.35 | 1,070,470.00 | 11.45 | 13.82 | 12.97 | 15.72 | 77.13 | 79.18 | 26.29 | 30.37 | 4.51 | 8.00 | 0.0595 | 28.58 | 17.06 | 16.85 | 17.07 | 11.22 | 37.93 | -- |
| Goodwill E-Health Info Co Ltd | 446.05m | -388.32m | 3.35bn | 1.87k | -- | 2.43 | -- | 7.52 | -2.82 | -2.82 | 3.24 | 10.04 | 0.1826 | 0.6860 | 0.5252 | 239,169.30 | -17.84 | -1.97 | -26.60 | -2.94 | 10.68 | 45.51 | -97.69 | -6.33 | 1.42 | -15.53 | 0.1827 | -- | -14.85 | 5.93 | -892.99 | -- | 94.81 | -- |
| Touchstone International Medi Sci Co Ltd | 314.11m | 81.09m | 3.45bn | 254.00 | 42.54 | 5.76 | -- | 10.99 | 1.00 | 1.00 | 3.92 | 7.39 | 0.4661 | 2.96 | 13.12 | 1,236,666.00 | 12.03 | 8.41 | 13.69 | 8.99 | 61.38 | 57.40 | 25.82 | 19.12 | 5.74 | -- | 0.0375 | 78.44 | 7.38 | 9.53 | 6.14 | 3.63 | 34.83 | -- |
Data as of Feb 06 2026. Currency figures normalised to Chemclin Diagnostics Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
1.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CCB Principal Asset Management Co., Ltd.as of 30 Jun 2025 | 871.24k | 0.32% |
| Maxwealth Fund Management Co., Ltd.as of 30 Jun 2025 | 760.91k | 0.28% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2025 | 751.70k | 0.27% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 242.53k | 0.09% |
| Penghua Fund Management Co., Ltd.as of 30 Jun 2025 | 165.31k | 0.06% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 139.30k | 0.05% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 139.27k | 0.05% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 123.45k | 0.05% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2025 | 114.80k | 0.04% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 111.89k | 0.04% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
